PortfoliosLab logoPortfoliosLab logo
GSK vs. ABDN.L
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

GSK vs. ABDN.L - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in GlaxoSmithKline plc (GSK) and Abrdn plc (ABDN.L). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Different Trading Currencies

GSK is traded in USD, while ABDN.L is traded in GBp. To make them comparable, the ABDN.L values have been converted to USD using the latest available exchange rates.

Returns By Period

In the year-to-date period, GSK achieves a 4.91% return, which is significantly lower than ABDN.L's 18.13% return. Over the past 10 years, GSK has outperformed ABDN.L with an annualized return of 4.64%, while ABDN.L has yielded a comparatively lower 2.69% annualized return.


GSK

1D
-1.71%
1M
1.25%
YTD
4.91%
6M
6.15%
1Y
27.36%
3Y*
17.87%
5Y*
4.68%
10Y*
4.64%

ABDN.L

1D
-0.87%
1M
5.07%
YTD
18.13%
6M
25.17%
1Y
36.61%
3Y*
14.82%
5Y*
3.78%
10Y*
2.69%
*Multi-year figures are annualized to reflect compound growth (CAGR)

GSK vs. ABDN.L - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
GSK
GlaxoSmithKline plc
4.91%51.23%-5.14%9.71%-33.41%26.74%-17.72%29.24%13.79%-2.97%
ABDN.L
Abrdn plc
18.13%69.86%-14.29%7.49%-23.98%-10.58%-2.46%44.40%-48.08%36.56%

Correlation

The correlation between GSK and ABDN.L is 0.13, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.13

Correlation (3Y)
Calculated over the trailing 3-year period

0.16

Correlation (5Y)
Calculated over the trailing 5-year period

0.20

Correlation (10Y)
Calculated over the trailing 10-year period

0.21

Correlation (All Time)
Calculated using the full available price history since Jul 5, 2007

0.31

The correlation between GSK and ABDN.L shifts across timeframes, from 0.13 (1 year) to 0.31 (all time), reflecting how their relationship changes across market environments.

Fundamentals

EPS

GSK:

$2.85

ABDN.L:

£0.70

PE Ratio

GSK:

17.78

ABDN.L:

3.39

PEG Ratio

GSK:

1.19

ABDN.L:

0.00

PS Ratio

GSK:

3.16

ABDN.L:

0.67

Total Revenue (TTM)

GSK:

$32.78B

ABDN.L:

£3.20B

Gross Profit (TTM)

GSK:

$23.87B

ABDN.L:

£3.05B

EBITDA (TTM)

GSK:

$11.30B

ABDN.L:

£796.00M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

GSK vs. ABDN.L — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GSK
GSK Risk / Return Rank: 6969
Overall Rank
GSK Sharpe Ratio Rank: 7373
Sharpe Ratio Rank
GSK Sortino Ratio Rank: 6868
Sortino Ratio Rank
GSK Omega Ratio Rank: 6565
Omega Ratio Rank
GSK Calmar Ratio Rank: 7070
Calmar Ratio Rank
GSK Martin Ratio Rank: 6969
Martin Ratio Rank

ABDN.L
ABDN.L Risk / Return Rank: 7979
Overall Rank
ABDN.L Sharpe Ratio Rank: 8080
Sharpe Ratio Rank
ABDN.L Sortino Ratio Rank: 7474
Sortino Ratio Rank
ABDN.L Omega Ratio Rank: 7676
Omega Ratio Rank
ABDN.L Calmar Ratio Rank: 8181
Calmar Ratio Rank
ABDN.L Martin Ratio Rank: 8484
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GSK vs. ABDN.L - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for GlaxoSmithKline plc (GSK) and Abrdn plc (ABDN.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


GSKABDN.LDifference
Sharpe ratioReturn per unit of total volatility

-0.21

Sortino ratioReturn per unit of downside risk

-0.19

Omega ratioGain probability vs. loss probability

1.19

1.23

-0.04

Calmar ratioReturn relative to maximum drawdown

1.48

2.19

-0.71

Martin ratioReturn relative to average drawdown

3.38

6.81

-3.42

GSK vs. ABDN.L - Sharpe Ratio Comparison

The current GSK Sharpe Ratio is 1.02, which is comparable to the ABDN.L Sharpe Ratio of 1.23. The chart below compares the historical Sharpe Ratios of GSK and ABDN.L, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


GSKABDN.LDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.02

1.23

-0.21

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.19

0.11

+0.08

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.20

0.07

+0.13

Sharpe Ratio (All Time)

Calculated using the full available price history

0.32

0.02

+0.30

Drawdowns

GSK vs. ABDN.L - Drawdown Comparison

The maximum GSK drawdown since its inception was -55.70%, smaller than the maximum ABDN.L drawdown of -73.92%. Use the drawdown chart below to compare losses from any high point for GSK and ABDN.L.


Loading charts...

Drawdown Indicators


GSKABDN.LDifference

Max Drawdown

Largest peak-to-trough decline

-55.70%

-73.92%

+18.22%

Max Drawdown (1Y)

Largest decline over 1 year

-18.63%

-16.65%

-1.98%

Max Drawdown (3Y)

Largest decline over 3 years

-28.46%

-39.30%

+10.84%

Max Drawdown (5Y)

Largest decline over 5 years

-50.10%

-61.23%

+11.13%

Max Drawdown (10Y)

Largest decline over 10 years

-50.10%

-70.03%

+19.93%

Current Drawdown

Current decline from peak

-15.91%

-23.97%

+8.06%

Average Drawdown

Average peak-to-trough decline

-18.87%

-37.49%

+18.62%

Ulcer Index

Depth and duration of drawdowns from previous peaks

8.11%

5.36%

+2.75%

Volatility

GSK vs. ABDN.L - Volatility Comparison

The current volatility for GlaxoSmithKline plc (GSK) is 6.42%, while Abrdn plc (ABDN.L) has a volatility of 8.19%. This indicates that GSK experiences smaller price fluctuations and is considered to be less risky than ABDN.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


GSKABDN.LDifference

Volatility (1M)

Calculated over the trailing 1-month period

6.42%

8.19%

-1.77%

Volatility (6M)

Calculated over the trailing 6-month period

18.51%

24.67%

-6.16%

Volatility (1Y)

Calculated over the trailing 1-year period

26.94%

29.76%

-2.82%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

25.06%

35.37%

-10.31%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

22.89%

36.99%

-14.10%

Dividends

GSK vs. ABDN.L - Dividend Comparison

GSK's dividend yield for the trailing twelve months is around 3.41%, less than ABDN.L's 6.18% yield.


PositionTTM20252024202320222021202020192018201720162015
ABDN.L
Abrdn plc
6.18%7.10%10.34%8.17%7.71%6.06%7.68%6.58%10.54%5.33%5.78%5.12%
GSK
GlaxoSmithKline plc
3.41%3.42%4.60%3.75%5.47%4.99%5.59%4.35%5.65%5.83%6.86%5.93%

Financials

GSK vs. ABDN.L - Financials Comparison

This section allows you to compare key financial metrics between GlaxoSmithKline plc and Abrdn plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.002.00B4.00B6.00B8.00B10.00B20222023202420252026
7.63B
1.04B
(GSK) Total Revenue
(ABDN.L) Total Revenue
Please note, different currencies. GSK values in USD, ABDN.L values in GBp

Frequently Asked Questions


GSK and ABDN.L have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Portfolio Optimizer

Find the right allocation for GSK and ABDN.L

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer